Related Experiment Video
Updated: Feb 3, 2026
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
Anne Rodallec1, Guillaume Sicard1, Raphaelle Fanciullino1
1a SMARTc Unit, Centre de Recherche en Cancérologie de Marseille UMR Inserm U1068 , Aix Marseille University , Marseille , France.
Introduction:
Immune checkpoint inhibitors have considerably changed the landscape of oncology. However apart from world-acclaimed success stories limited to melanoma and lung cancer, many solid tumors failed to respond to immune checkpoint inhibitors due to limited immunogenicity, unfavorable tumor micro-environments (TME), lack of infiltrating T lymphocytes or increases in Tregs. Areas covered: Combinatorial strategies are foreseen as the future of immunotherapy and using cytotoxics or modulating agents is expected to boost the efficacy of immune checkpoint inhibitors. In this respect, nanoparticles displaying unique pharmacokinetic features such as tumor targeting properties, optimal payload delivery and long-lasting interferences with TME, are promising candidates for such combinations. This review covers the basis, expectancies, limits and pitfalls of future combination between nanoparticles and immune check point inhibitors. Expert opinion: Nanoparticles allow optimal delivery of variety of payloads in tumors while sparing healthy tissue, thus triggering immunogenic cell death. Depleting tumor stroma could further help immune cells and monoclonal antibodies to better circulate in the TME, plus immune-modulating properties of the charged cytotoxics. Finally, nanoparticles themselves present immunogenicity and antigenicity likely to boost immune response at the tumor level.
Insights
Nanoparticles combined with immune checkpoint inhibitors show promise for treating solid tumors. This approach enhances drug delivery and boosts the immune system
Area of Science:
- Oncology
- Immunotherapy
- Nanomedicine
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but efficacy is limited in many solid tumors due to poor immunogenicity and unfavorable tumor microenvironments (TME).
- Strategies to overcome resistance to ICIs are crucial for expanding their therapeutic potential.
- Combinatorial approaches are essential for enhancing ICI efficacy in challenging cancers.
Purpose of the Study:
- This review explores the potential of combining nanoparticles with immune checkpoint inhibitors for cancer therapy.
- It examines the benefits, challenges, and future directions of this innovative therapeutic strategy.
Main Methods:
- The review synthesizes current research on nanoparticle-based drug delivery systems.
- It analyzes how nanoparticles can modulate the tumor microenvironment and enhance immune responses.
- Expert opinion on the integration of nanoparticles with immunotherapies is discussed.
Main Results:
- Nanoparticles offer targeted delivery of therapeutic payloads to tumors, minimizing off-target effects.
- They can trigger immunogenic cell death and modify the TME to improve immune cell infiltration.
- Nanoparticles possess inherent immunogenicity and antigenicity, potentially augmenting anti-tumor immunity.
Conclusions:
- Combining nanoparticles with ICIs represents a promising strategy to improve treatment outcomes in solid tumors.
- Nanoparticles can enhance the efficacy of ICIs by improving drug delivery, modulating the TME, and stimulating anti-tumor immune responses.
- Further research is needed to optimize nanoparticle design and clinical application for combination immunotherapy.
More Related Videos
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Related Concept Videos
01:27Tumor Immunotherapy
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment
01:21Masonry in Cold and Hot Weather Conditions
Other key practices include keeping masonry units...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...